BCL2 derived genetic elements associated with sensitivity to che

Details BCL2 derived genetic elements associated with sensitivity to che BCL2 derived genetic elements associated with sensitivity to che

1995-03-17

1998-08-04

Degen, Nancy

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 245, A01N 4304

Patent

active

057893896

ABSTRACT:
The invention provides genetic suppressor elements that are derived from the apoptosis-related gene BCL2. The invention provides genetic suppressor elements that are capable of inhibiting BCL2 gene expression and BCL2-mediated suppression of apoptosis in mammalian cells. The GSEs provided by the invention are also useful for sensitizing cancer cells to the cytotoxic effects of chemotherapeutic drugs. The invention provides methods for identifying and obtaining such elements, and therapeutic methods of using such elements for treatment of cancer cells and animals bearing malignant tumors.

REFERENCES:
patent: 5015568 (1991-05-01), Tsujimoto et al.
patent: 5217889 (1993-06-01), Roninson et al.
Orkin, et al. 1995, "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy".
Gura, T. 1995. Science. vol. 270. pp. 575-577. "Antisense Has Growing Pains".

Affiliated with

Also associated with

Rating

BCL2 derived genetic elements associated with sensitivity to che does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BCL2 derived genetic elements associated with sensitivity to che, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BCL2 derived genetic elements associated with sensitivity to che will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1177279